Posted on September 18th, 2014
Mr. Commissiong was appointed President and CEO of Amarantus BioScience in October 2011.
Amarantus BioScience Holdings, Inc. is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. The Company has licensed Eltoprazine (“Eltoprazine”), a phase 2b ready indication for Parkinson’s Levodopa induced dyskinesia and Adult ADHD. The Company has an exclusive worldwide license to the Lymphocyte Proliferation test (“LymPro Test®”) for Alzheimer’s disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor (“MANF”) and is developing MANF-based products as treatments for brain disorders. Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property for the diagnosis of Parkinson’s disease (“NuroPro”) and the discovery of neurotrophic factors (“PhenoGuard”).
Management is acutely aware of the depreciation in the value of our equity over the last several weeks. We have undertak...Read More »
Posted on September 16th, 2014
Over the weekend, the New York Times published a front-page article entitled; “Brain Trauma to Affect One in Three...Read More »
Posted on September 15th, 2014
It is my pleasure to introduce you to Targeted Medical Pharma (TRGM) with my first blog in a series of informative discu...Read More »
Posted on September 10th, 2014
Are pandemic viral pathogens establishing a global foothold? At present, the deadliest Ebola virus outbreak in history...Read More »
Posted on September 5th, 2014
Capstone Therapeutics Corp. (OTCQB: CAPS) is a “fallen angel,” reflected by the Company’s current market cap of $1...Read More »
Reveal Insights About Your Company and Industry to Shareholders.
The Chairman's Blog is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. The Chairman's Blog enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. Learn More »